Advertisement

Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology

Published:October 06, 2017DOI:https://doi.org/10.1016/j.ejca.2017.09.007

      Highlights

      • The limitations of randomised clinical trials to evidence-based medicine are reviewed.
      • Complementary strategies based on exploiting population-based registries and electronic health records are discussed.
      • A novel approach combining population-based registry and electronic health record features is proposed.

      Abstract

      Randomised clinical trials (RCTs) are considered the basis of evidence-based medicine. It is recognised more and more that application of RCT results in daily practice of clinical decision-making is limited because the RCT world does not correspond with the clinical real world. Recent strategies aiming at substitution of RCT databases by improved population-based registries (PBRs) or by improved electronic health record (EHR) systems to provide significant data for clinical science are discussed. A novel approach exemplified by the HemoBase haemato-oncology project is presented. In this approach, a PBR is combined with an advanced EHR, providing high-quality data for observational studies and support of best practice development. This PBR + EHR approach opens a perspective on randomised registry trials.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sackett D.L.
        • Rosenberg W.M.
        • Gray J.A.
        • Haynes R.B.
        • Richardson W.S.
        Evidence based medicine: what it is and what it isn't.
        BMJ. 1996 Jan 13; 312: 71-72
        • Lauer M.S.
        • D'Agostino R.B.S.
        The randomized registry trial–the next disruptive technology in clinical research?.
        N Engl J Med. 2013 Oct 24; 369: 1579-1581
        • Cherubini A.
        • Pierri F.
        • Gasperini B.
        • Zengarini E.
        • Cerenzia A.
        • Bonifacio E.
        • et al.
        Are ongoing trials on hematologic malignancies still excluding older subjects?.
        Haematologica. 2013 Jul; 98: 997-1000
        • Stewart W.F.
        • Shah N.R.
        • Selna M.J.
        • Paulus R.A.
        • Walker J.M.
        Bridging the inferential gap: the electronic health record and clinical evidence.
        Health Aff (Millwood). 2007 Mar-Apr; 26: w181-w191
        • Perlin J.B.
        • Kupersmith J.
        Information technology and the inferential gap.
        Health Aff (Millwood). 2007 Mar-Apr; 26: w192-w194
        • Coebergh J.W.
        • van den Hurk C.
        • Rosso S.
        • Comber H.
        • Storm H.
        • Zanetti R.
        • et al.
        EUROCOURSE lessons learned from and for population-based cancer registries in europe and their programme owners: improving performance by research programming for public health and clinical evaluation.
        Eur J Cancer. 2015 Jun; 51: 997-1017
        • Wu S.G.
        • Li H.
        • Tang L.Y.
        • Sun J.Y.
        • Zhang W.W.
        • Li F.Y.
        • et al.
        The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis.
        Tumour Biol. 2017 Jun; 39https://doi.org/10.1177/1010428317705082
        • Lau C.S.M.
        • Zywot A.
        • Mahendraraj K.
        • Chamberlain R.S.
        Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973-2013).
        HPB Surg. 2017; 2017: 1532835
        • Siesling S.
        • Louwman W.J.
        • Kwast A.
        • van den Hurk C.
        • O'Callaghan M.
        • Rosso S.
        • et al.
        Uses of cancer registries for public health and clinical research in europe: results of the european network of cancer registries survey among 161 population-based cancer registries during 2010-2012.
        Eur J Cancer. 2015 Jun; 51: 1039-1049
        • Sant M.
        • Minicozzi P.
        • Mounier M.
        • Anderson L.A.
        • Brenner H.
        • Holleczek B.
        • et al.
        Survival for haematological malignancies in europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
        Lancet Oncol. 2014 Aug; 15: 931-942
        • Dandoit M.
        • Mounier M.
        • Guy J.
        • Petrella T.
        • Girard S.
        • Casasnovas R.O.
        • et al.
        The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.
        Leuk Lymphoma. 2015 Apr; 56: 1050-1057
        • Dickhoff C.
        • Dahele M.
        • Smit E.F.
        • Paul M.A.
        • Senan S.
        • Hartemink K.J.
        • et al.
        Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: results from The Netherlands cancer registry.
        Lung Cancer. 2017 Aug; 110: 14-18
        • van Spronsen D.J.
        • Post P.N.
        • Crommelin M.A.
        • Breed W.P.
        • Coebergh J.W.
        Modest decline in late mortality following hodgkin's disease in the southeastern Netherlands since 1972.
        Ann Hematol. 1998 May; 76: 205-209
        • Blimark C.
        • Holmberg E.
        • Mellqvist U.H.
        • Landgren O.
        • Bjorkholm M.
        • Hultcrantz M.
        • et al.
        Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
        Haematologica. 2015 Jan; 100: 107-113
        • Jones G.L.
        • Taylor P.R.
        • Windebank K.P.
        • Hoye N.A.
        • Lucraft H.
        • Wood K.
        • et al.
        Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of hodgkin's lymphoma in adolescents.
        Br J Cancer. 2007 Jul 2; 97: 29-36
        • Dal Maso L.
        • Tavilla A.
        • Pacini F.
        • Serraino D.
        • van Dijk B.A.C.
        • Chirlaque M.D.
        • et al.
        Survival of 86,690 patients with thyroid cancer: a population-based study in 29 european countries from EUROCARE-5.
        Eur J Cancer. 2017 May; 77: 140-152
        • Gavin A.
        • Rous B.
        • Marcos-Gragera R.
        • Middleton R.
        • Steliarova-Foucher E.
        • Maynadie M.
        • et al.
        Towards optimal clinical and epidemiological registration of haematological malignancies: guidelines for recording progressions, transformations and multiple diagnoses.
        Eur J Cancer. 2015 Jun; 51: 1109-1122
        • Liu L.
        • Giusti F.
        • Schaapveld M.
        • Aleman B.
        • Lugtenburg P.
        • Meijnders P.
        • et al.
        Survival differences between patients with hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands cancer registry linked data with 20 years of follow-up.
        Br J Haematol. 2017 Jan; 176: 65-75
        • Proctor S.J.
        • Wilkinson J.
        A web-based study concept designed to progress clinical research for 'orphan' disease areas in haematological oncology in the elderly: the SHIELD programme.
        Crit Rev Oncol Hematol. 2007 Jan; 61: 79-83
        • Coebergh J.W.
        • van den Hurk C.
        • Louwman M.
        • Comber H.
        • Rosso S.
        • Zanetti R.
        • et al.
        EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees in europe: from roots to fruits.
        Eur J Cancer. 2015 Jun; 51: 1050-1063
        • Blommestein H.M.
        • Franken M.G.
        • Uyl-de Groot C.A.
        A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
        Pharmacoeconomics. 2015 Jun; 33: 551-560
        • Oerlemans S.
        • Issa D.E.
        • van den Broek E.C.
        • Nijziel M.R.
        • Coebergh J.W.
        • Huijgens P.C.
        • et al.
        Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
        Ann Hematol. 2014 Oct; 93: 1705-1715
        • Danaei G.
        • Rodriguez L.A.
        • Cantero O.F.
        • Logan R.
        • Hernan M.A.
        Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.
        Stat Methods Med Res. 2013 Feb; 22: 70-96
        • Boslooper K.
        • Kibbelaar R.
        • Storm H.
        • Veeger N.J.
        • Hovenga S.
        • Woolthuis G.
        • et al.
        Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.
        Leuk Lymphoma. 2014 Mar; 55: 526-532
        • Wieringa A.
        • Boslooper K.
        • Hoogendoorn M.
        • Joosten P.
        • Beerden T.
        • Storm H.
        • et al.
        Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
        Br J Haematol. 2014 May; 165: 489-496
        • Boslooper K.
        • Hoogendoorn M.
        • van Roon E.N.
        • Kibbelaar R.E.
        • Storm H.
        • Hovenga S.
        • et al.
        No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status.
        Cancer Epidemiol. 2017 Jun; 48: 110-116
        • Oortgiesen B.E.
        • van Roon E.N.
        • Joosten P.
        • Kibbelaar R.E.
        • Storm H.
        • Hovenga S.
        • et al.
        The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.
        Eur J Clin Pharmacol. 2017 Jun; 73: 771-778
        • de Vries J.C.
        • Oortgiesen B.
        • Hemmelder M.H.
        • van Roon E.
        • Kibbelaar R.E.
        • Veeger N.
        • et al.
        Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.
        Leuk Lymphoma. 2017 Sep; 58: 1-9
        • Cowie M.R.
        • Blomster J.I.
        • Curtis L.H.
        • Duclaux S.
        • Ford I.
        • Fritz F.
        • et al.
        Electronic health records to facilitate clinical research.
        Clin Res Cardiol. 2017 Jan; 106: 1-9
        • Cooke C.R.
        • Iwashyna T.J.
        Using existing data to address important clinical questions in critical care.
        Crit Care Med. 2013 Mar; 41: 886-896
        • Angus D.C.
        Fusing randomized trials with big data: the key to self-learning health care systems?.
        JAMA. 2015 Aug 25; 314: 767-768
        • Kanas G.
        • Morimoto L.
        • Mowat F.
        • O'Malley C.
        • Fryzek J.
        • Nordyke R.
        Use of electronic medical records in oncology outcomes research.
        Clin Outcomes Res. 2010; 2: 1-14
        • Denis F.
        • Lethrosne C.
        • Pourel N.
        • Molinier O.
        • Pointreau Y.
        • Domont J.
        • et al.
        Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients.
        J Natl Cancer Inst. 2017 Sep 1; 109https://doi.org/10.1093/jnci/djx029